99 patents currently held
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Sep 2032. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Sep 2032
Next term end
42
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Oct 2037 · High confidence
Also notable
Ends Mar 2034 · High confidence
Also notable
Ends Apr 2034 · High confidence
Oxysterols and Methods of Use Thereof
US 11,149,054
Cited by 31 later US patents, top 5% of utility patents granted in 2021 in our data. Protection runs to 2037.
Neuroactive Steroids and Methods of Use Thereof
US 11,104,701
Cited by 35 later US patents, top 5% of utility patents granted in 2021 in our data. Protection runs to 2034. A terminal disclaimer caps this term to an earlier patent's.
19-NOR C3, 3-Disubstituted C21-N-PYRAZOLYL Steroids and Methods of Use Thereof
US 9,512,165
Cited by 105 later US patents, top 5% of utility patents granted in 2016 in our data, and renewed at every maintenance window due so far. Protection runs to 2034.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 4 fees due Dec 6 to 25, 2026 · next Dec 6
- 1 fee due Jan 9, 2027The maintenance fee for 19-NOR C3, 3-Disubstituted C21-N-PYRAZOLYL Steroids and Methods of Use Thereof (US 10,342,810) comes due Jan 9, 2027. Unpaid by Jul 9, 2027, it lapses early.
- 4 fees due Feb 8 to 27, 2027 · next Feb 8
- 3 fees due Apr 1 to 10, 2027 · next Apr 1
- 1 fee due Jun 26, 2027The maintenance fee for Oxysterols and Methods of Use Thereof (US 11,851,457) comes due Jun 26, 2027. Unpaid by Dec 27, 2027, it lapses early.
- 3 fees due Jul 23 to 30, 2027 · next Jul 23
- 3 fees due Aug 20 to 27, 2027 · next Aug 20
- 2 fees due Sep 3 to 12, 2027 · next Sep 3
- 3 fees due Oct 2 to 30, 2027 · next Oct 2
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
The 5 largest of its 42 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Neuroactive Steroids and Their Methods of Use | 6 in force | to Dec 2039 |
| Neuroactive Steroids, Compositions, and Uses Thereof | 5 in force | to Jun 2035 |
| 19-NOR C3, 3-Disubstituted C21-N-PYRAZOLYL Steroids and Methods of Use Thereof | 5 in force | to Feb 2035 |
| Compositions and Methods for Treating CNS Disorders | 4 in force | to Jul 2036 |
| Neuroactive Steroids and Methods of Use Thereof | 4 in force | to Mar 2034 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,759,828 | Neuroactive Steroids, Compositions, and Uses Thereof In force · Medium confidence | In force | Medium confidence | |
| US 12,129,275 | Neuroactive Steroids, Compositions, and Uses Thereof In force · Medium confidence | In force | Medium confidence | |
| US 10,435,431 | 3,3 Disubstituted 19-NOR Pregnane Compounds, Compositions, and Uses Thereof In force · High confidence | In force | High confidence | |
| US 10,322,139 | Neuroactive Steroid Formulations and Methods of Treating CNS Disorders In force · High confidence | In force | High confidence | |
| US 11,426,417 | Neuroactive Steroid Formulations and Methods of Treating CNS Disorders In force · High confidence | In force | High confidence | |
| US 12,048,706 | Methods of Treating Epilepsy or Status Epilepticus In force · High confidence | In force | High confidence | |
| US 9,630,986 | Neuroactive 19-Alkoxy-17-Substituted Steroids, Prodrugs Thereof, and Methods of Treatment Using Same In force · High confidence | In force | High confidence | |
| US 9,676,812 | Neuroactive 19-Alkoxy-17-Substituted Steroids, Prodrugs Thereof, and Methods of Treatment Using Same In force · High confidence | In force | High confidence | |
| US 10,227,375 | Neuroactive Steroids and Methods of Use Thereof In force · High confidence | In force | High confidence | |
| US 11,104,701 | Neuroactive Steroids and Methods of Use Thereof In force · High confidence | In force | High confidence |
Also on record, not counted in the 99: 1 patent in force now held by others · 66 applications pending · 85 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.